Physician profile
Leonil Ganlim
NPI 1962512590
$19,068.87
in general payments reported to CMS, 2019-2025
59 companies · $2,966 in 2025
The $2,966 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,471 · 2020: $2,074 · 2021: $3,130 · 2022: $2,918 · 2023: $2,439 · 2024: $3,071 · 2025: $2,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,382 · Education: $94.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,381.70 |
| Education | $94.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,162.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,699.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,388.06 | 2019-2025 | Evenity, Prolia, Repatha |
| Corcept Therapeutics | $1,227.74 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $1,189.49 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $1,010.36 | 2019-2025 | Omnipod |
| Dexcom, INC. | $987.38 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $946.60 | 2019-2025 | |
| Abbott Laboratories | $889.59 | 2019-2025 | Freestyle Libre 3, Freestyle Libre, Eterna |
| Medtronic, INC. | $756.73 | 2021-2025 | Minimed 780g, Intellis Adaptivestim, Minimed 770g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $721.57 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $618.27 | 2019-2025 | |
| Recordati_rare_diseases_inc. | $526.58 | 2021-2025 | Isturisa, Signifor Lar |
| Amarin Pharma, INC. | $473.84 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $465.93 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonil Ganlim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.